000			01285 a2200385 4500
005			20250512021433.0
264		0	_c19891208
008			198912s 0 0 eng d
022			_a0250-7005
040			_aNLM _beng _cNLM
100	1		_aPollak, M N
245	0	0	_aSomatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. _h[electronic resource]
260			_bAnticancer research _c
300			_a889-91 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aArginine
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aColonic Neoplasms _xdrug therapy
650	0	4	_aFemale
650	0	4	_aGrowth Hormone _xblood
650	0	4	_aHumans
650	0	4	_aInsulin-Like Growth Factor I _xanalysis
650	0	4	_aKidney Neoplasms _xdrug therapy
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aOctreotide _xtherapeutic use
650	0	4	_aOvarian Neoplasms _xdrug therapy
650	0	4	_aPancreatic Neoplasms _xdrug therapy
650	0	4	_aSomatomedins _xanalysis
700	1		_aPolychronakos, C
700	1		_aGuyda, H
773	0		_tAnticancer research _gvol. 9 _gno. 4 _gp. 889-91
999			_c2823677 _d2823677